Abstract

A large number of pharmaceutical drugs possess one or more centers of asymmetry giving rise to enantiomers whose pharmacological properties and toxicity are often different. At successive stages of drug discovery, the enantiomers of any chiral molecule must be isolated and analyzed and their enantiomeric purity determined. The electrophoretic and chromatographic techniques have become the most important tools to routinely determine the enantiomeric purity of pharmaceutical molecules. Liquid chromatography (LC) is the most widely used because of the large number of columns marketed, the variety of selectivities available and the ease at which analytical results can be scaled up to the preparative level. In particular, more than 80% of enantioseparations of pharmaceutical molecules are successful with polysaccharide-derivative stationary phases (cellulose, amylose) for multiple system solvents (normal phase, polar organic phase or reverse phase). Complementary selectivities can be achieved more rapidly with other types of stationary phase (glycopeptides, Pirkle, cyclodextrins) but their application is hindered by problems of stability (proteins) or transfer to the preparative scale (cyclodextrins). At the present time, glycopeptide phases offer very promising prospects for the separation of amino acids (and derivatives) and peptide enantiomers. In addition, because of its faster analysis and environmental benefits, supercritical chromatography (SFC) has given rise to renewed interest. Capillary electrophoresis (CE) is an orthogonal technique complementary to chromatographic methods. Its principle involves the formation of diastereoisomer complexes after addition of anionic (HS-beta-CD, HS-gamma-CD CM-beta-CD) or neutral (TM-beta -CD, HP-beta-CD, DM-beta-CD, HP-gamma-CD) cyclodextrins to the running buffer. Compared to LC, CE analyses are cheaper (no chiral column, no solvent, low consumption of chiral selector) and peak efficiencies are higher by one order of magnitude. Furthermore, the mechanism of separation in CE is much simpler to understand and predict. However, the low capacity of CD column prevents its use at the preparative scale and consequently hampers its development as an analytical technique. Today, the increasing number of new drug candidate molecules produced daily, and for which the determination of enantiomeric purity is required before further development, encourages the pharmaceutical industry to seek fast chiral analysis methods based on simple protocols. The speed of analysis is more important than resolution. Thus, screening strategies are implemented with HPLC, SFC and CE including the selection of a limited number of chiral selectors with strong powers of chiral recognition.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.